Drug Approval | December 28, 2021
India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod
It plans to deliver over 300 million doses to the Indian government
It plans to deliver over 300 million doses to the Indian government
The drug will be marketed under the brand name Molnaflu
The Home Healthcare market is expected to be US $ 14.2 by 2025
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The company has started manufacturing the Sputnik Light vaccine
Subscribe To Our Newsletter & Stay Updated
